biostudies-literatureFenor de la Maza MDCancer Research UKNational Institute for Health Research (NIHR)Wellcome Trust659-667https://www.ebi.ac.uk/biostudies/studies/S-EPMC7617991biostudies-literatureUnknown5(6)<h4>Background</h4>Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact on the care of these patients, but the availability of metastatic tissue samples for research in this setting is limited.<h4>Objective</h4>To study the prevalence of immune biomarkers of potential clinical utility to immunotherapy in mCRPC and to determine their association with overall survival (OS).<h4>Design, setting, and participants</h4>From 100 patients, mCRPC biopsies were assayed by whole exome sequencing, targeted next-generation sequencing, RNA sequencing, tumor mutational burden, T-cell-inflamed gene expression profile (TcellinfGEP) score European urology oncologyImmune Biomarkers in Metastatic Castration-resistant Prostate Cancer.PMC7617991219594/Z/19/ZNF-SI-0617-10099Sharp AChandran Kde Bono JSLiu XQCarreira SBertan CRiisnaes RWestaby DRodrigues DNRekowski JSchloss CSeed GCross EGurel BCristescu RYuan WFigueiredo IFerreira AShui IMFenor de la Maza MDMiranda SRescigno PTunariu NYap CGil VCrespo MfalseImmune Biomarkers in Metastatic Castration-resistant Prostate Cancer.<h4>Background</h4>Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact on the care of these patients, but the availability of metastatic tissue samples for research in this setting is limited.<h4>Objective</h4>To study the prevalence of immune biomarkers of potential clinical utility to immunotherapy in mCRPC and to determine their association with overall survival (OS).<h4>Design, setting, and participants</h4>From 100 patients, mCRPC biopsies were assayed by whole exome sequencing, targeted next-generation sequencing, RNA sequencing, tumor mutational burden, T-cell-inflamed gene expression profile (TcellinfGEP) score 2022-01-01T00:00:00Z2022 Dec2026-04-15T19:25:25.495Z2026-04-07T14:01:21.665ZS-EPMC76179913549135610.1016/j.euo.2022.04.004